P-113 COVID 19 AND CIRRHOSIS, A DEADLY COMBINATION. WHAT HAPPENS IN ECUADOR?

INTRODUCTION: COVID-19 represents a great threat in patients with cirrhosis, being a poor prognostic factor. Since the first COVID 19 case in Ecuador 02/29/2020, its impact on cirrhotics in this country is unknown. AIM: To determine the morbidity and mortality of cirrhotic patients with COVID 19. Is it higher in relation to cirrhotics without COVID 19? METHODS: The present study was multicenter, observational, analytical, prospective and cross-sectional, included 147 hospitalized patients from 2 health units in Guayaquil-Ecuador (Hospital General HOSNAG and Hospital “Abel Gilbert Pontón”), from February 29, 2020 to February 28, 2021. Two groups were established: A, cirrhotic patients with COVID 19; group B, cirrhotic without COVID 19, the following tests were used: Student's T, U Mann-Whitney continuous variables and chi-square, Fisher's exact categorical variables; Statistical analysis was performed with SPSS version 21. RESULTS: Of the 147 included, Group A led by male sex 40 patients (52.6%), female sex 36 (47.4%), distribution according to child pugh was 10 (13.6%) stage A, 36 (47, 3%) stage B and 30 (39.4%) stage C, causes of admission were: SRI 59 (77.6%), febrile syndrome 15 (19.7%), encephalopathy 2 (2.6%), average days of hospitalization 13 (± 6.4), associated mortality was 28 (36.8%) most frequent causes of death; SRI 19 (25%), ACLF 8 (10.5%), AMI 1 (1.3%). Group B, male sex 32 patients (54.5%), female 29 (45.5%), child pugh A only 2 patients (3.2%), stage B 30 (49.1%) and C with 29 (47.5%), reason for admission more frequent was UGB 27 (44.2%), ascites 22 (36%), encephalopathy 9 (14.7%), febrile syndrome 3 (4.9%), average days hospitalized 11 (± 5), mortality of 27.8%, causes of death; UGB 9 (14.7%), ACLF 5 (8.1%) and encephalopathy 3 (4.9%) (P 0.002). CONCLUSION: The morbidity and mortality of cirrhotic patients with Covid 19 was higher than those without Covid 19.